Oppenheimer Holdings, Inc. Reaffirms Hold Rating for Clovis Oncology, Inc. (CLVS)
Several other research firms have also commented on CLVS. ValuEngine lowered Clovis Oncology from a hold rating to a sell rating in a research note on Friday, May 19th. BidaskClub raised Clovis Oncology from a hold rating to a buy rating in a research report on Wednesday, June 21st. Cann reissued a hold rating on shares of Clovis Oncology in a research report on Monday. Evercore ISI assumed coverage on Clovis Oncology in a research report on Wednesday, August 16th. They issued an in-line rating and a $73.00 target price for the company. Finally, SunTrust Banks, Inc. reaffirmed a buy rating on shares of Clovis Oncology in a research report on Thursday, June 22nd. Eight research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $85.16.
Clovis Oncology (NASDAQ CLVS) opened at 70.78 on Monday. The stock’s market capitalization is $3.46 billion. The stock’s 50 day moving average price is $75.80 and its 200-day moving average price is $68.70. Clovis Oncology has a 12-month low of $25.50 and a 12-month high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.27) by ($0.02). The company had revenue of $14.62 million during the quarter, compared to analysts’ expectations of $13.07 million. The company’s revenue was down 32.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.07) EPS. Analysts expect that Clovis Oncology will post ($7.53) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/14/oppenheimer-holdings-inc-reaffirms-hold-rating-for-clovis-oncology-inc-clvs.html.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $91.56, for a total value of $274,680.00. Following the completion of the transaction, the insider now owns 197,583 shares in the company, valued at $18,090,699.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James C. Blair sold 18,450 shares of Clovis Oncology stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the completion of the transaction, the director now owns 2,185 shares of the company’s stock, valued at approximately $171,762.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,450 shares of company stock valued at $1,935,185. Corporate insiders own 17.40% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Phocas Financial Corp. bought a new position in Clovis Oncology in the 2nd quarter worth approximately $112,000. First Mercantile Trust Co. acquired a new stake in Clovis Oncology during the 1st quarter worth $115,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Clovis Oncology by 71.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 758 shares during the period. Advisors Asset Management Inc. grew its holdings in shares of Clovis Oncology by 160.7% in the 2nd quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 1,168 shares during the period. Finally, Legato Capital Management LLC acquired a new position in shares of Clovis Oncology in the 2nd quarter valued at $220,000. Hedge funds and other institutional investors own 98.94% of the company’s stock.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.